Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · SPDR (State Street)

State Street(R) Health Care Select Sector SPDR(R) ETF (XLV)

Ticker XLV · · Holdings as of Jun 30, 2026

Expense ratio
0.08%$8/yr per $10k
5-yr return
+8.1%annualized
1-yr return
+14.5%as of Dec 2025
Net assets
$40.6Ball share classes
Holdings
65

Bottom line

Is XLV a good fund? The bottom line

XLV is a managed health care sector ETF from SPDR (State Street).

It charges 0.08% — about $8 a year on every $10,000 invested, cheaper than 99% of health care sector funds we track.

It returned +14.5% over one year, +8.1% a year over five years, +9.8% a year over ten (as of Dec 31, 2025, per its prospectus).

With $40.6 billion in net assets and 65 holdings, its largest position is Eli Lilly & Co (16.5%) and the top 10 make up 61.5% of the portfolio.

What stands out

  • Low cost: cheaper than 99% of health care sector peers
  • 5-year return beat 94% of category peers
  • Large and established ($40.6 billion)

What to watch

  • Concentrated: top 10 holdings are 61.5% of assets
  • 12b-1 marketing fee of 0.02% a year

Updated Nov 19, 2026

What XLV invests in

State Street Health Care Select Sector SPDR ETF (the Fund) seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index (the Index).

In seeking to track the performance of the Index, the Fund employs a replication strategy, which means that the Fund typically invests in substantially all of the securities represented in the Index in approximately the same proportions as the Index. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. The Fund will provide shareholders with at least 60 days' notice prior to any material change in this 95% investment policy. In addition, the Fund may invest in cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds (including money market funds advised by SSGA Funds Management, Inc. ( SSGA FM or the Adviser), the investment adviser to the Fund). The Index includes companies that have been identified as Health Care companies by the…

From the fund's prospectus (filed Jan 28, 2026).

XLV performance

Fund calendar-year total returns, 2016–2025 2016: −2.8%; 2017: +21.7%; 2018: +6.3%; 2019: +20.7%; 2020: +13.3%; 2021: +25.9%; 2022: −2.1%; 2023: +2.0%; 2024: +2.5%; 2025: +14.5% −3% 2016 +22% 2017 +6% 2018 +21% 2019 +13% 2020 +26% 2021 −2% 2022 +2% 2023 +3% 2024 +15% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
XLV+14.5%+8.1%+9.8%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full XLV performance history →

What XLV costs

On a $10,000 investment, XLV's 0.08% expense ratio costs about $8 a year. The prospectus estimates $103 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full XLV fee table →

XLV top 10 holdings

#Holding% of fund
1Eli Lilly & Co16.51%
2Johnson & Johnson10.64%
3AbbVie Inc7.74%
4UnitedHealth Group Inc6.57%
5Merck & Co Inc5.52%
6Amgen Inc3.40%
7Thermo Fisher Scientific Inc3.24%
8Abbott Laboratories2.75%
9Gilead Sciences Inc2.73%
10Intuitive Surgical Inc2.45%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 61.5% of the fund. See all top 25 holdings and asset mix →

Alternatives to XLV

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%98% Compare
VanguardVHT Vanguard Health Care Index Fund0.09%94% Compare
iSharesIYH iShares U.S. Healthcare ETF0.37%90% Compare
J.P. MorganJDOC JPMorgan Healthcare Leaders ETF0.65%62% Compare
SchwabSWHFX Schwab Health Care Fund0.8%76% Compare
T. Rowe PricePRHSX T. Rowe Price Health Sciences Fund, Inc.0.83%80% Compare

More funds like XLV →

XLV FAQ

What is the expense ratio of XLV?
XLV's expense ratio is 0.08%, which works out to about $8 a year for every $10,000 invested. The prospectus estimates total costs of $103 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is XLV a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 99% of health care sector peers; 5-year return beat 94% of category peers; large and established ($40.6 billion); concentrated: top 10 holdings are 61.5% of assets; 12b-1 marketing fee of 0.02% a year. This is general information, not personalized advice.
What does XLV hold?
XLV's largest holdings are Eli Lilly & Co (16.5%), Johnson & Johnson (10.6%), AbbVie Inc (7.7%), UnitedHealth Group Inc (6.6%), Merck & Co Inc (5.5%). It holds 65 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is XLV's 5-year return?
XLV returned +8.1% a year over the five years ending Dec 31, 2025, and +9.8% a year over ten years. Past performance does not guarantee future results.
What is a cheaper alternative to XLV?
FHLC (Fidelity MSCI Health Care Index ETF) overlaps about 98% with XLV and charges 0.084%.
Who manages XLV?
XLV is offered by SPDR (State Street) through Select Sector Spdr Trust.